Valuation : Etropal AD

Market Cap 22.54M 13.54M 11.68M 10.99M 10.01M 18.82M 1.28B 18.92M 130M 50.55M 654M 50.83M 49.73M 2.17B P/E 2023
-129x
P/E 2024 247x
Enterprise Value 26.61M 15.98M 13.79M 12.97M 11.81M 22.22M 1.52B 22.34M 153M 59.67M 772M 60M 58.7M 2.56B EV / Sales 2023
2.42x
EV / Sales 2024 1.63x
Free-Float
48.99%
Yield 2023 *
-
Yield 2024 -
1 day-1.50%
1 week-1.50%
1 month-5.07%
3 months+13.91%
6 months+13.91%
Current year+14.03%
1 week 2.1
Extreme 2.1
2.66
1 month 2.1
Extreme 2.1
2.66
Current year 2.1
Extreme 2.1
2.76
1 year 2.04
Extreme 2.044493
2.76
3 years 1.94
Extreme 1.935661
2.76
5 years 1.94
Extreme 1.935661
3.48
10 years 0.51
Extreme 0.511256
3.48
Manager TitleAgeSince
Chief Executive Officer - 1997-12-31
Investor Relations Contact - -
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 1997-12-31
Director/Board Member - 2006-12-31
Chairman - 2014-12-03
Change 5-day change 1-year change 3-year change Capi.($)
-1.50%-1.50%+25.45%+2.53% 15.21M
+2.31%+1.49%-23.40%-40.22% 16.05B
+4.03%+19.54%+56.55%+168.07% 5.32B
-0.43%-1.14%+234.77%+205.71% 3.2B
+1.56%+4.98%-29.39%-29.29% 2.52B
-0.13%+1.22%-31.55%-26.37% 1.82B
-3.79%-4.51%+8.55%-16.99% 1.31B
-0.84%+0.42%+4.76%-17.74% 1.04B
+5.77%+11.77%+12.08%+19.23% 970M
+5.22%-8.49%+126.71%+159.50% 968M
Average +1.19%+0.26%+38.45%+42.44% 3.32B
Weighted average by Cap. +1.85%+0.75%+20.99%+27.66%

Financials

2023 2024
Net sales 11.2M 6.73M 5.8M 5.46M 4.97M 9.35M 638M 9.4M 64.52M 25.11M 325M 25.25M 24.71M 1.08B 15.75M 9.46M 8.16M 7.67M 6.99M 13.15M 898M 13.22M 90.72M 35.31M 457M 35.51M 34.74M 1.51B
Net income -28K -16.82K -14.51K -13.65K -12.43K -23.38K -1.6M -23.5K -161K -62.79K -812K -63.14K -61.77K -2.69M 87K 52.25K 45.07K 42.4K 38.63K 72.63K 4.96M 73.03K 501K 195K 2.52M 196K 192K 8.36M
Net Debt 4.08M 2.45M 2.11M 1.99M 1.81M 3.4M 232M 3.42M 23.49M 9.14M 118M 9.2M 9M 392M 4.07M 2.44M 2.11M 1.98M 1.81M 3.4M 232M 3.42M 23.44M 9.12M 118M 9.18M 8.98M 391M
Logo Etropal AD
Etropal AD is a Bulgaria-based company, which specializes in the scientific research, experimental and development activities in the field of orthopedics and traumatology. The Company manufactures and offers endoprothesys and implants, special bioceramic materials and alloys for the medicine, special surgical instruments, osteosynthesys means, single use syringes, haemodialysis apparatuses and lines and single use medical materials. The Company’s product portfolio includes fiber dialyzers, arterial and venous lines for haemodialysis, transfusion and infusion sets, fistula and injection needles, catheters, tubes, and femoral implants, among others. The Company operates through one subsidiary, Etropal Trade OOD. As of December 31, 2011, the Company’s major shareholder was Sintetika AD with a stake of 66.53%.
Employees
100
Date Price Change Volume
26-08-31 €2.620 -1.50% 90
26-08-26 €2.660 -.--% 20
26-08-25 €2.660 -.--% 40